Latest Breaking News On - Junshi - Page 1 : comparemela.com

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

AI-Driven Optical Network Technology Transformation: China FIBERTalk 2024 Takes Place in China's Optics Valley

WUHAN, China, May 23, 2024 /PRNewswire/ Co-hosted by the Fiber Network Council APAC and Yangtze Optical Fibre and Cable Joint Stock Limited Company , China FIBERTalk 2024 was held in China s.

China generalNishiguchi yukiMelanie germentilRaadjkoemar mataiOptical network technologiesCommunication engineering centerChina telecomChina unicom research instituteCommunications technologyCable joint stock limited companyUniversity of milanGrid information telecommunication branchDivision of optical communicationChina telecommunication technology labsChina mobile group design instituteChina telecom research institute

Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs

Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesPaul reiderCoherus biosciencesAmgen neulastaJunshi biosciences partnered

Garsorasib Plus Cetuximab Shows Early Efficacy in Heavily Pretreated KRAS G12C+ CRC

The combination of garsorasib and cetuximab elicited responses and was found to be well tolerated in heavily pretreated patients with KRAS G12C–mutated colorectal cancer.

Rui hua xuKeymed bioscienceBristol myers squibbClinical researchSun yat sen university cancer centerColorectal cancer

Fierce Pharma Asia—Merck KGaA and Hengrui's PARP deal; Novartis and Takeda's employee dispute; toripalimab's FDA nod

Fierce Pharma Asia—Merck KGaA and Hengrui's PARP deal; Novartis and Takeda's employee dispute; toripalimab's FDA nod
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Coherus biosciencesDaiichi sankyoAstrazeneca lynparzaDenny lanfearMerck kgaMerck coMerck kgaaJiangsu hengrui pharmaceuticalKhaled shams eldinNovarti egyptTakeda egyptJunshi biosciences partnered